A clear path forward: the latest innovation in kidney transplant surveillance can drive better outcomes for your patients.
AlloSure is the first and only non-invasive test which assesses organ health by directly measuring allograft injury.
AlloSure is a clinically and analytically validated, non-invasive blood test that measures donor-derived cell-free DNA (dd-cfDNA), an indicator of kidney injury.
AlloSure can accurately determine active rejection, enabling better management of your kidney transplant patients.